FLT3 and acute myeloid leukemia: Nevertheless, while it is true that midostaurin-mediated inhibition of tyrosine kinases is effective against AML, other tyrosine kinase inhibitors (e.g., gilteritinib and quizartinib) also show significantly improved clinical events in patients with FLT3-mutated AML [66,67].